EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, UCB's Enterprise Value is €25,087 Mil.
UCB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €585 Mil. Therefore, UCB's EV-to-EBIT for today is 42.88.
The historical rank and industry rank for UCB's EV-to-EBIT or its related term are showing as below:
WBO:UCB'
s EV-to-EBIT Range Over the Past 10 Years
Min: 5.65 Med: 14.23 Max: 44.09
Current: 42.89
During the past 13 years, the highest EV-to-EBIT of UCB was 44.09. The lowest was 5.65. And the median was 14.23.
WBO:UCB's EV-to-EBIT is ranked worse than 84.23% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs WBO:UCB: 42.89
The historical data trend for UCB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, UCB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where UCB's EV-to-EBIT falls into.
UCB's current Enterprise Value is €25,087 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. UCB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €585 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (WBO:UCB) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
UCB's Enterprise Value for the quarter that ended in Dec. 2023 was €16,933 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. UCB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €585 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of UCB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WBO:UCB has been successfully added to your 